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ABSTRACT
Neoadjuvant chemo(radio)therapy followed by surgery is the standard of care for 
patients with locally advanced resectable esophageal adenocarcinoma (EAC). There is 
increasing evidence that drug resistance might be related to genomic heterogeneity. 
We investigated whether genomic tumor heterogeneity is different after cytotoxic 
chemotherapy and is associated with EAC patient survival. We used arrayCGH and a 
quantitative assessment of the whole genome DNA copy number aberration patterns 
(‘DNA copy number entropy’) to establish the level of genomic tumor heterogeneity 
in 80 EAC treated with neoadjuvant chemotherapy followed by surgery (CS group) 
or surgery alone (S group). The association between DNA copy number entropy, 
clinicopathological variables and survival was investigated.
DNA copy number entropy was reduced after chemotherapy, even if there was 
no morphological evidence of response to therapy (p<0.001). Low DNA copy number 
entropy was associated with improved survival in the CS group (p=0.011) but not in 
the S group (p=0.396).
Our results suggest that cytotoxic chemotherapy reduces DNA copy number 
entropy, which might be a more sensitive tumor response marker than changes in 
the morphological tumor phenotype. The use of DNA copy number entropy in clinical 
practice will require validation of our results in a prospective study.
INTRODUCTION
Pre-operative or peri-operative 5-fluorouracil/
cisplatin based chemotherapy as well as pre-operative 
chemoradiotherapy followed by radical resection are 
the standard of care for patients with locally advanced, 
resectable esophageal adenocarcinoma (EAC) [1-3]. 
However, only 20 to 30% of EAC patients currently 
achieve a durable remission after multimodality treatment 
[4, 5]. Thus, there is an urgent clinical need to better 
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understand the molecular processes that are involved in 
disease progression and resistance to therapy.
Cytotoxic chemotherapy exerts one of the strongest 
selection pressures on cancer cells implying that 
chemotherapy treatment may favor the persistence of 
treatment resistant subpopulations [6].
It has been suggested that drug resistance might be 
related to genomic tumor heterogeneity [7]. High levels 
of genomic tumor heterogeneity in pre-treatment biopsies 
have been related to poor response to chemotherapy 
in EAC [8], as well as been related to poor outcome in 
head and neck cancers [9] and adenocarcinomas of the 
lung [10]. However, when measured in paired samples 
taken before and after chemotherapy, results are variable 
showing no change in genomic tumor heterogeneity in 
breast and ovarian cancer [11, 12], decreasing genomic 
tumor heterogeneity in acute myeloid leukemia [13] and 
newly acquired genomic changes in acute lymphoblastic 
leukemia [14].
Several studies have demonstrated the existence 
of genomic and/or phenotypic tumor heterogeneity in 
EAC [15-20]. The presence of genomic heterogeneity 
in Barrett’s esophagus, an endoscopically identifiable 
precursor lesion of EAC, is predictive of progression to 
adenocarcinoma [17], and its presence in pre-treatment 
EAC biopsies has been related to poor chemotherapy 
response [8]. The relationship between genomic tumor 
heterogeneity and patient outcome and the effect of 
cytotoxic chemotherapy on genomic tumor heterogeneity 
have not been investigated in EAC to date.
Whole genome copy number profiling using 
array comparative genomic hybridization (aCGH) can 
provide a snapshot of the global DNA copy number 
aberration pattern. In this hypothesis-generating study, 
we used aCGH to quantify the degree of genomic tumor 
heterogeneity within a group of samples by estimating 
the DNA copy number entropy [21]. This allowed us to 
explore the differences in the DNA copy number entropy 
between EAC patients from the OE02 trial treated with 
neoadjuvant chemotherapy (CS group) and those treated 
by surgery alone (S group), and to examine the association 
of DNA copy number entropy with clinicopathological 
variables, histopathologically measured tumor regression 
grade according to Mandard and patient survival.
RESULTS
Relationship between DNA copy number 
entropy, treatment group and histopathological 
tumor regression grade
This study used DNA copy number entropy as 
a surrogate marker of genomic tumor heterogeneity. A 
representative DNA copy number profile with low DNA copy 
number entropy value and one with a high DNA copy number 
entropy value are shown in Figure 1A and 1B, respectively.
EAC in the CS group had a significantly lower DNA 
copy number entropy value compared to EAC in the S 
group (median DNA copy number entropy (range) CS 
group: -0.524 (-1.801 to 1.289) versus S group: 0.321 
(-1.411 to 1.315), p<0.001, Figure 2), indicating that 
EACs in the CS group had DNA copy number aberrations 
at relatively similar genomic locations. The differences 
and similarities in DNA copy number profiles between 
the CS and the S group can also be seen in a principal 
component scatter plot, Figure 3. These plots show that 
the DNA copy number values (as summarized by their first 
two principal components) from the S group were much 
more spread out (Figure 3B) than those from the CS group 
(Figure 3A), indicating that the variation of the DNA copy 
number aberrations between EACs in the S group is higher 
than between EACs in the CS group. In other words, the 
inter-tumor heterogeneity of the aCGH profile is reduced 
in EACs after chemotherapy.
The comparison of the DNA copy number entropy 
values between the CS group and the S group stratified 
by chromosome showed that DNA copy number entropy 
values for chromosome 1 and chromosome 5 were 
significantly different. Median DNA copy number entropy 
(range) of chromosome 1 was -0.296 (-4.165 to 1.213) 
in the CS group compared to 0.483 (-3.070 to 1.645) in 
the S group, p=0.001. Similarly, the median DNA copy 
number entropy (range) of chromosome 5 was -0.271 
(-3.800 to 1.255) in the CS group compared to 0.413 
(-3.238 to 1.647) in the S group, p=0.03. However, related 
to the very high complexity of the aCGH profiles, we 
were not able to identify specific probes or genes neither 
on chromosome 1 nor on chromosome 5 which were 
significantly different between the treatment groups after 
applying rigorous multiple testing corrections. For all 
other chromosomes, the DNA copy number entropy values 
were not statistically significantly different between the 
CS and the S group (Supplementary Figure S5 and S6).
Although the median DNA copy number entropy 
values increased with increasing Mandard tumor 
regression grade category e.g. the highest DNA copy 
number entropy values were seen in EAC with no 
histological evidence of tumor regression (Mandard 
grade 5), this relationship was not statistically significant 
(Mandard grade 3 median DNA copy number entropy: 
-1.597; Mandard grade 4: -0.696; Mandard grade 5: 
-0.292, p > 0.1). The lack of statistical significance could 
be related to the relatively small sample size in the current 
study. Interestingly, the DNA copy number entropy values 
of EACs in the S group were significantly higher than 
the DNA copy number entropy values of EACs in the CS 
group with no histological evidence of tumor regression 
(Mandard grade 5, n=26) (median (range) DNA copy 
number entropy of Mandard grade 5 EACs in the CS 
group: -0.292 (-1.801 to 0.685), median (range) DNA copy 
number entropy in the S group: 0.321 (-1.411 to 1.315), p< 
0.001, Figure 4).
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Figure 1: Array CGH profile and DNA copy number entropy. A. Low DNA copy number entropy case showing a profile 
with relative few aberrations (sample no. 74, y-axis: log2 ratio of DNA signal from the tumor to matched normal, x-axis: chromosomes 
in numerical order; DNA copy number entropy: -1.541766, MAD value 0.34), B. High DNA copy number entropy case showing many 
aberrations (gains/amplifications as well as losses) (sample no. 91, y-axis: log2 ratio of DNA signal from the tumor to matched normal, 
x-axis: chromosomes in numerical order; DNA copy number entropy: 0.5224006, MAD value: 0.33). Note that both samples have similar 
MAD values (estimates of the noise) indicating that there was no technical difference in the quality of the array CGH experiment.
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Figure 2: Normalised DNA copy number entropy distribution by treatment group. The polygon shape of the bean plot shows 
the distribution of the DNA copy number entropy values within each group. The DNA copy number entropy distribution is significantly 
different between CS and S (p< 0.001) with a higher mean DNA copy number entropy in the S group. Patients treated by surgery alone (S 
group, right side of the panel), patients treated by chemotherapy and surgery (CS group, left side of the panel). Line perpendicular to the 
long axis of the panel = mean DNA copy number entropy/group; DNA copy number entropy values on the y axis.
Figure 3: Scatterplot after principal component analysis of the DNA copy number profile by treatment group. Plotting 
the segmented DNA copy number profiles using its principal components shows inter-tumor variation within each treatment group (A. CS 
group; B. S group). Each triangle denotes a sample. Each shaded area was created by connecting samples with the same variation level. 
The smaller the shaded area, the more similar the samples within the group. The scatter plots show that there is less inter-tumor variation in 
the CS group which is indicative of a higher level of inter-tumor homogeneity reflected in a low DNA copy number entropy value. In the 
surgery alone group, sample values are more spread out in the plot indicating a higher degree of inter-tumor variation reflected in a higher 
DNA copy number entropy value.
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Relationship between DNA copy number 
entropy, clinicopathological variables and 
patient survival
No association was found between depth of tumor 
invasion (pT/ypT), lymph node status (pN/ypN), grade 
of differentiation, lymphatic channel invasion, venous 
invasion or perineural invasion, and DNA copy number 
entropy neither when investigating these associations by 
treatment arm nor in the combined group (Supplementary 
Table S1).
As a consequence of our case selection (selecting 
short-term and long-term survivors in both groups, see 
Material and Methods), the survival was not significantly 
different between the S and CS group. Thus, initial 
survival analyses were performed combining the two 
groups. Low DNA copy number entropy was significantly 
associated with longer cancer specific survival in the 
whole patient group (HR: 1.382, 95%CI: 1.014-1.884, 
p=0.041). For Kaplan-Meier survival analysis, three equal 
sized patient groups were created based on the DNA copy 
number entropy values. As the survival curves of two of 
these groups overlapped substantially (Supplementary 
Figure S4), these two groups were subsequently merged. 
Kaplan-Meier survival analysis showed that the group of 
patients with low DNA copy number entropy (≤ -0.5670), 
e.g. with DNA copy number aberrations at similar 
genomic locations, survived significantly longer than 
patients with high DNA copy number entropy, e.g. DNA 
copy number aberration at multiple different genomic 
locations, p=0.024, Figure 5A. Cross tabulation between 
DNA copy number entropy group and treatment group 
indicated that 29 (83%) S group patients fell into the high 
DNA copy number entropy group (entropy > -0.5670), 
whereas patients from the CS group were equally 
distributed between the high and low DNA copy number 
entropy group (Figure 5). This observation prompted us 
to further explore the relationship between DNA copy 
number entropy and survival by treatment arm.
Cox regression analysis using continuous DNA 
copy number entropy values showed that DNA copy 
number entropy was significantly associated with cancer 
specific survival in the CS group (HR: 1.775, 95% CI: 
1.047-3.009, p=0.033) but not in the S group (HR: 1.144, 
95%CI: 0.699-1.871, p=0.593). For visualization of the 
Cox regression analysis results, Kaplan-Meier survival 
plots were created stratifying patients by using the 
median DNA copy number entropy per treatment group 
Figure 4: Normalised DNA copy number entropy distribution comparing the surgery alone (S group) samples with no 
pathological response (Mandard tumor regression grade 5) with samples after chemotherapy (CS group). The polygon 
shape of the bean plot shows the distribution of the DNA copy number entropy values within each group. The DNA copy number entropy 
of EAC from patients treated by surgery alone (right side of the panel) is significantly higher than that of EAC treated with neoadjuvant 
chemotherapy showing no histopathological evidence of tumor regression (left side of the panel), p<0.001. Line perpendicular to the long 
axis of the panel = mean DNA copy number entropy/group; DNA copy number entropy values on the y axis.
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as cut-off. CS group patients with low DNA copy number 
entropy had a significantly better survival (median (range) 
survival time: 6.9 years (0 to 15.6 years)) compared to 
CS group patients with high DNA copy number entropy 
(0.9 years (0.7 to 0.97 years), p=0.011, Figure 5B). No 
relationship between DNA copy number entropy and 
survival was found in the S group patients (p=0.396, 
Figure 5C). Cox regression analysis showed that there is 
no evidence of a treatment interaction effect (treatment 
interaction p=0.654). Hence, we have no evidence that 
the effect of the DNA copy number entropy depends on 
the treatment.
Comparison of the DNA copy number profile 
and DNA copy number entropy with previous 
studies
In order to assess whether the aCGH profiles and 
DNA copy number entropy of EAC of the current study 
are comparable to previously published EAC DNA 
copy number data, the frequency of DNA copy number 
aberrations and DNA copy number entropy of the S 
group EACs were compared to two recently published 
data sets [22, 23]. Visual inspection of the DNA copy 
number aberration frequency plots from all three studies 
Figure 5: DNA copy number entropy and cancer specific survival. A. Kaplan-Meier survival analysis of the combined patient 
cohort. Patients with low DNA copy number entropy (n=27), dichotomized using the median (-0.5670) as a cut-off, have a significantly 
longer survival than those with high DNA copy number entropy (n=50). Median (95% CI) survival time low DNA copy number entropy 
6.94 years (0.56-13.28 years) versus high DNA copy number entropy 0.85 years (0.56-1.14 years), log rank p=0.024. More than 80% of S 
patients have tumors with high DNA copy number entropy (see crosstable). B. Kaplan-Meier survival analysis of the CS group patients. 
DNA copy number entropy dichotomised at the median. CS patients with low DNA copy number entropy have a significantly longer 
survival than those with high DNA copy number entropy (median (95% CI) survival time low DNA copy number entropy 6.94 years (0-
15.59) vs. high DNA copy number entropy 0.86 years (0.74-0.971), log rank p=0.011). C. Kaplan-Meier survival analysis of the S group 
patients. DNA copy number entropy dichotomised at the median. No relationship was seen between DNA copy number entropy and 
survival in S patients (log rank p=0.396).
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was performed and profiles were deemed to be similar on 
visual inspection (Figure 6A to 6C).
Relationship between DNA copy number entropy 
and percentage of tumor cells/area
EAC from the CS group had a median of 70% 
tumor cells/area ranging from 30 to 90% (Supplementary 
Figure S2). EAC from the S group had a median of 50% 
tumor cells/area ranging from 30 to 70%. There was no 
association between the DNA copy number entropy and the 
estimated tumor percentage/area neither in the CS group 
nor the S group (p=0.412 and p=0.531, respectively). There 
was also no significant difference in the percentage of tumor 
cells/area between the long-term and short-term survivors in 
any of the groups (CS: p=0.103; S: p=0.439). We observed 
neither considerable differences in scatterness between the 
high and the low tumor cells/area groups nor differences 
in scatterness when each treatment group was analyzed 
separately (Supplementary Figure S3).
DISCUSSION
There have been a number of DNA copy number 
studies in esophageal adenocarcinoma (EAC) in the past, 
reporting different candidate genes or group of genes 
related to tumor progression or patient survival [18-20, 
23-26]. A common finding of all previous EAC studies as 
well as the current study is that the overall level of DNA 
copy number alterations in EAC was very high leading 
to very complex DNA copy number profiles. However, 
only few aberrations were shared across more than 10% 
of samples supporting the existence of a high degree of 
genomic tumor heterogeneity in EAC.
The frequency of DNA copy number aberrations 
(irrespective of the genes involved) has been related to 
Figure 6: Comparison of the data from the surgery alone group of the current study with previously published datasets 
from patients with esophageal adenocarcinoma. A–C. Mean DNA copy number aberrations plotted by chromosome position 
(x-axis) using segmented data points present in all datasets. Gains = above the 0 line, loss = below the 0 line. The profile of the DNA 
copy number data from the S group patients from the current study (A, n=35) is visually similar to that previously published by Goh et al 
(B, n=53) and to that previously published by Dulak et al. (C, n=74, 16321 probes).
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survival in EAC in some but not all studies [23-25]. The 
current study is the first study to quantify the DNA copy 
number entropy by whole genome aCGH as a surrogate 
measure of genomic inter-tumor heterogeneity using 
DNA extracted from resection material from patients who 
were either treated by surgery alone (S group) or by 5FU/
cisplatin chemotherapy followed by surgery (CS group) as 
part of the OE02 trial [1].
We found no relationship between DNA 
copy number entropy and any of the investigated 
clinicopathological data neither in the S group nor in the 
CS group. Importantly, there was also no statistically 
significant association between DNA copy number entropy 
and Mandard tumor regression grade of the primary tumor 
(only investigated in the CS group) or percentage of tumor/
area (investigated in both groups). These results provide 
some confidence that the DNA copy number entropy is 
not simply a surrogate of some other pathological variable 
or known prognostic factor. Our findings are consistent 
with results reported in head and neck cancer where the 
variability of the mutant-allele fraction was used as marker 
of genomic tumor heterogeneity [9].
Our study showed that EACs after chemotherapy 
have DNA copy number profiles in which the aberrations 
were found more frequently at relatively similar locations, 
making them more ‘homogenous’ when measured by DNA 
copy number entropy compared to chemo-naïve EACs 
(Figure 3). In contrast, Almendro et al [11] reported a 
change in the morphological but not the genomic phenotype 
of the tumor cells in breast cancer after chemotherapy. Our 
study showed no difference in the morphological tumor 
phenotype comparing EAC from the S group with those 
from the CS group with Mandard grade 5 (no pathological 
response). However, we found a significant difference in 
the genomic phenotype between Mandard grade 5 EACs 
from the CS group and EACs from the S group. This 
discrepancy between studies could be related to different 
tumor types (EAC vs. breast cancer) as well as substantial 
differences in investigated markers (whole genome vs. few 
selected markers) used to characterize the tumor phenotype 
and genotype. Further studies in a larger sample size need 
to verify whether DNA copy number entropy might be a 
clinically useful biomarker of response to chemotherapy.
Our analyses comparing the DNA copy number 
entropy per chromosome between treatment groups showed 
that the difference in the DNA copy number entropy was 
strongly associated with the DNA copy number entropy in 
chromosome 1 and 5. The underlying mechanisms for this 
finding are currently unclear and warrant future studies. 
So far, there is no evidence from previous aCGH studies 
suggesting clinically relevant candidate genes on these 
particular chromosomes in EAC and we were unable to 
identify any individual significantly different probe or group 
of genes on these chromosomes in the current study.
Low DNA copy number entropy was only related 
to better outcome in EAC patients who had received 
chemotherapy prior to surgery. Mroz et al [9] reported the 
relation between tumor heterogeneity and patient outcome 
in head and neck cancer patients treated by surgery 
alone as well as in those treated with chemotherapy. 
Murugaesu et al [8] reported that intra-tumoral genomic 
heterogeneity of the pre-treatment biopsy is related to poor 
response to platinum based chemotherapy. However, both 
studies determined genomic tumor heterogeneity prior to 
chemotherapy, whereas we measured DNA copy number 
in material after chemotherapy, hence results are not 
directly comparable.
We compared the aCGH profiles and the DNA copy 
number entropy of the surgery alone group with published 
data sets [22, 23]. Visual inspection showed that major 
aberrations like copy number losses in chromosome 
(Chr) 3, gains in Chr7, Chr8 and Chr20 were present in 
all studies. Hence, we think that findings in this study 
were unlikely to be dataset specific. Due to difference 
in platforms and hence differences in data resolution, 
statistical assessment and quantification of the differences 
were not possible. Since, post-chemotherapy aCGH data 
from EAC have not been published to date, no comparison 
to previous data could be made for this group.
In conclusion, this is the first study to quantify 
genomic tumor heterogeneity in esophageal 
adenocarcinoma, and to suggest that it might contribute to 
survival differences after chemotherapy.
Our result requires validation in a larger 
independent cohort ideally comparing pre- and post-
chemotherapy samples from the same tumor to directly 
measure the change in DNA copy number entropy 
induced by chemotherapy. The presence of genomic 
tumor heterogeneity, together with low frequencies of 
common aberrations across multiple cancers, makes the 
identification of predictive/prognostic biomarkers in EAC 
challenging, unless DNA copy number entropy itself 
can be used for this purpose. For the first time, we can 
show that cytotoxic chemotherapy appears to effect the 
tumor genotype (DNA copy number) in cases where the 
human eye cannot see any changes in the histological 
phenotype, suggesting that we might need to re-evaluate 
and potentially adapt the morphology based assessment 
criteria of primary tumor regression grading in particular 
in cases with a high tumor cell content per area.
A better understanding of the mechanisms leading 
to genomic tumor heterogeneity is urgently needed before 
novel therapeutic strategies can be developed and outcome 
of EAC patients can finally be improved.
MATERIALS AND METHODS
Esophageal adenocarcinoma patient cohort
The UK MRC OE02 trial recruited 802 patients 
with locally advanced esophageal cancer who were 
randomized to either two cycles of cisplatin/5-fluorouracil 
(5-FU) followed by surgery (CS group) or treatment by 
surgery alone (S group) between 1992 and 1998 [1]. 
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Formalin-fixed and paraffin-embedded (FFPE) tissue 
blocks from the resection specimens were retrospectively 
collected from 510 OE02 trial patients. For this pilot 
study, 40 patients from the CS group and 40 patients 
from the S group were selected based on the availability 
of appropriate material for DNA extraction and the 
following criteria: (1) presence of adenocarcinoma in the 
pre-treatment biopsy, (2) CS patients were known to have 
received at least one cycle of pre-operative chemotherapy, 
(3) patients were reported to have died from esophageal 
cancer. In order to increase the chance to detect potential 
prognostic markers within treatment groups, patients were 
further selected based on their survival time to ensure that 
in each treatment group 50% patients that had died within 
12 months after randomization (short-term survivors) and 
50% had survived at least 36 months after randomization 
(long-term survivors). Consequently, this selection 
resulted in a data set with large differences in survival 
within treatment groups and no survival difference 
between treatment groups (p=0.62). Median (range) 
follow up of short-term survivors was 0.72 years (0.28 to 
0.97 years) and 0.46 years (0.30 to 0.67 years) in the CS 
and S group, respectively. Median (range) follow up of 
long-term survivors was 7.65 years (3.07 to 10.76 years) 
and 7.30 years (3.23 to 11.62 years) in the CS and S group, 
respectively. The median age (range) was 60.1 years (39.8 
to 83.15 years) and 65.13 years (40.87 to 75.77 years) in 
the CS and S group, respectively.
The hematoxylin and eosin stained glass slides 
from all retrieved resection specimens and the original 
histopathology reports were reviewed to establish the 
histopathology data set used for analyses. Regression 
of the primary tumor was graded according to Mandard 
et al [27] centrally. Cases were staged according to the 
6th edition of the TNM classification [28]. Details of the 
clinicopathological data of the patient cohort can be found 
in Table 1.
DNA extraction and DNA copy number analysis
The tumor cell content per macrodissected tumor 
tissue area was estimated. As it had been shown previously 
that DNA copy number analyses from tumors with less 
than 30% tumor cells/area can be severely compromised 
[29], five cases (all from the S group) with less than 30% 
tumor cells/area had to be excluded from further analyses. 
DNA was extracted from a single FFPE tissue block 
containing the highest tumor cell density per area as well 
as from normal tissue (lymph node or normal esophageal 
wall) from the same patient as described previously [30].
High-resolution array comparative genomic 
hybridization (aCGH) was performed using custom 
design 180K Agilent microarrays (4x180k array, Agilent 
Technologies, Palo Alto, CA, USA, GEO platform 
GPL8687) containing 180,880 in situ synthesized 
oligonucleotides representing 169,793 unique 
chromosomal locations evenly distributed over the 
genome (spacing ~17 kb) and 4548 additional unique 
oligonucleotides, located at 238 of the Cancer Census 
genes (http://www.sanger.ac.uk/genetics/CGP/Census/).
Oligonucleotide positions were defined according to 
the NCBI36/hg18 assembly (March 2006). Labeling and 
hybridization were performed as described previously by 
Buffart et al [31]. Agilent’s feature extraction software 
(v10.5.1.1) with default settings was used to quantify the 
fluorescence intensities of all 180,880 features. aCGH 
data have been deposited in NCBI’s Gene Expression 
Omnibus and are accessible through GEO accession 
number GSE56106.
aCGH data pre-processing
aCGH data were generated from 75 cases. The raw 
data underwent a series of pre-processing steps, which 
are detailed in Section S1 of the Supplementary file. The 
pre-processing was performed within the R statistical 
environment. After quantification, control spots (n=6,539) 
were removed from the data yielding 174,341 features. 
Both channels were background corrected by subtracting 
background median intensities from foreground median 
intensities to obtain an unbiased hybridization signal. 
Normalization, cellularity correction and segmentation 
were performed with the R-package CGHcall [32]. The 
median absolute deviation (MAD) was calculated for all 
probes from all chromosomes as described by [33] as a 
measure of the technical quality of the aCGH experiment. 
All statistical analyses were performed using segmented 
data.
Statistical analyses
DNA copy number profiles of the patients 
included in the current study were compared with two 
previously published DNA copy number data sets (Gene 
Expression Omnibus (GEO) database accession number: 
GSE36460 and GSE20154) [22, 23]. All raw datasets 
were pre-processed and segmented following the same 
procedures as used in this study. The genomic locations 
of CGH probes across studies were matched using the 
R-package sigaR [34] and a mean segmented data profile 
(average across samples) was generated for each data set 
(Supplementary Figure S1).
Next, we quantified the degree of genomic tumor 
heterogeneity for each case by assessing the overall 
DNA copy number aberration pattern and estimating the 
DNA copy number entropy using the segmented data 
and the R-package sigaR [34] (see supplementary file 
for mathematical description of the entropy calculation). 
The mean DNA copy number entropy was compared 
between treatment groups using permutation for 
p-value calculation, where the test statistic equals the 
entropy difference between the groups. To visualize the 
intersample heterogeneity, as measured by the DNA copy 
number entropy, the segmented data matrix was projected 
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on its first two principal components and scatter plots were 
generated for each treatment group.
The DNA copy number entropy of a sample without 
DNA copy number aberrations, such as normal tissue, 
is very low to minimal. Tumor samples can have near 
zero, few or many DNA copy number aberrations and, 
thus, the DNA copy number entropy value can range 
from minimal/low to high [21]. In order to investigate 
the potential contribution of an individual chromosome 
to the observed difference in DNA copy number entropy 
between treatment groups, the entropy-based data analysis 
approach was also applied to each chromosome separately.
To establish whether there was any relationship 
between differences in the DNA copy number entropy and 
tumor cellularity of the sample, we constructed a linear 
model with tumor cellularity as confounder. Furthermore, 
the segmented data profiles of <50% (low cellularity) 
and >= 50% (high cellularity) samples in each treatment 
Table 1: Clinicopathological data by treatment arm (CS: chemotherapy + surgery; S: surgery alone)
CS n (%) S n (%)
40 (53) 35 (47)
Gender
 Female 8 (20) 4 (11)
 Male 32 (80) 31 (89)
Number of deaths due to cancer 30 (75) 27 (77)
Depth of tumor invasion (pT/ypT)
 T1 7 (19) 4 (11)
 T2 2 (5) 4 (11)
 T3 31 (76) 27 (78)
Lymph node status (pN/ypN)
 N0 13 (33) 7 (20)
 N1 27 (67) 28 (80)
Lymphatic channel invasion
 Absent 27 (67) 15 (43)
 Present 13 (33) 20 (57)
Blood vessel invasion
 Absent 36 (90) 28 (80)
 Present 4 (10) 7 (20)
Peri- or intraneural invasion
 Absent 25 (62) 13 (37)
 Present 15 (38) 22 (63)
Grade of differentiation (worst)#
 Well 3 (8) 0
 Moderate 13 (33) 6 (17)
 Poor 23 (58) 29 (83)
Mandard tumor regression grade*
 3 3 (7) -
 4 11 (28)
 5 26 (65)
#one missing value in the CS group.
*tumor regression grading not applicable for surgery alone cases.
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arm were projected on its first two principal components 
separately, for visual inspection of the difference in 
scatterness.
The association between DNA copy number entropy 
and cancer specific survival was investigated using a Cox 
proportional hazards model. The potential prognostic 
value of the treatment, in addition to DNA copy number 
entropy, was investigated in a Cox proportional hazards 
model.
The associations between DNA copy number 
entropy and tumor regression grade (CS group only), 
depth of invasion (pT/ypT), lymph node status (pN/
ypN) and grade of differentiation were investigated using 
the test statistic implemented in the R-package sigaR. 
P-values <0.05 were considered statistically significant 
for single tests, and Benjamini-Hochberg corrected false 
discovery rates (FDR) <0.1 were considered statistically 
significant for multiple tests. Statistical analyses were 
performed using R, version 3.0.
The study was approved by the London – South East 
ethics committee (REC reference: 07/H1102/111).
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